PT - JOURNAL ARTICLE AU - Shreya Ghosh AU - Akansha Garg AU - Chayanika Kala AU - Ashwani Kumar Thakur TI - Amyloid deposition in granuloma of tuberculosis patients: A pilot study AID - 10.1101/2021.02.08.21250526 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.08.21250526 4099 - http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250526.short 4100 - http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250526.full AB - The formation of granuloma is one of the characteristic feature of tuberculosis. Besides, rise in the concentration of acute phase response proteins mainly serum amyloid A is the indicator for chronic inflammation associated with tuberculosis. Serum amyloid A drives secondary amyloidosis in tuberculosis and other chronic inflammatory conditions. The linkage between serum amyloid A (SAA) protein and amyloid deposition site is not well understood in tuberculosis and other chronic inflammatory conditions. We hypothesized that granuloma could be a potential site for amyloid deposition because of the presence of serum amyloid A protein and proteases that cleave SAA and trigger amyloid formation. Based on this hypothesis, for the first time we have shown the presence of amyloid deposits in the granuloma of tuberculosis patients using the gold standard, Congo red dye staining.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GSVM Medical College Ethics committee Approval:YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot ApplicableTBtuberculosisWHOworld health organizationFDAFood and Drug AdministrationSAAserum amyloid AH&EHematoxylin and eosinFFPEformalin fixed paraffin embeddedCRCongo redMMPsmatrix metalloproteinasesMtbMycobacterium tuberculosis